Loading...
ROCO
4147
Market cap586mUSD
Jul 09, Last price  
69.50TWD
1D
-1.84%
1Q
26.36%
Jan 2017
-58.26%
IPO
-35.89%
Name

TaiMed Biologics Inc

Chart & Performance

D1W1MN
ROCO:4147 chart
P/E
—
P/S
30.77
EPS
—
Div Yield, %
—
Shrs. gr., 5y
1.46%
Rev. gr., 5y
-3.29%
Revenues
611m
+0.19%
00319,000135,00000002,076,0008,436,000241,041,000704,504,000722,485,000413,442,000563,008,000491,777,000610,162,000611,350,000
Net income
-168m
L-16.87%
-374,064,000-220,815,000-238,207,000-204,520,000-207,298,000-251,677,000-281,735,000-471,680,000-281,962,000-524,554,000-321,710,000-579,010,000-187,392,000-478,377,000-279,388,000-194,810,000-201,832,000-167,776,000
CFO
191m
P
-171,313,000-186,925,000-134,413,000-117,231,000-164,684,000-213,084,000-446,265,000-172,295,000-516,483,000-522,856,000-655,314,000-201,936,000-211,275,000-605,210,000-25,601,000-379,552,000191,144,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

TaiMed Biologics Inc., a biotechnology company, develops, manufactures, and commercializes drugs for the treatment and prevention of infectious diseases. The company develops and markets Trogarzo IV infusion and Trogarzo IV push, a monoclonal antibody for HIV treatment. It is also developing TMB-365, a monoclonal antibody used for HIV treatment and prevention which has completed a phase-1 clinical trial; and TMB-365 and TMB-380 combination, a monoclonal antibody combination therapy for HIV that is in phase-1b/2a clinical trial, as well as antibody-drug conjugates for cancer treatment. In addition, the company offers contract development and manufacturing services. It has a research and development agreement with Genentech and Biogen Inc. for Trogarzo TMB-355; and authorizes Samsung Biologics to produce TMB-355. TaiMed Biologics Inc. was incorporated in 2007 and is headquartered in Taipei, Taiwan.
URL
http://www.taimedbiologics.com/
IPO date
Jun 28, 2010
Employees
Domiciled in
TW
Incorporated in
TW

Valuation

Title
TWD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2025‑122024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT